Acute Leukemia
Conditions
Brief summary
This post hoc analysis included patients with acute leukemia who underwent allo-HSCT at the First Affiliated Hospital of Zhejiang University School of Medicine and Ruijin Hospital Shanghai Jiaotong University School of Medicine. Patients and their donors were assessed for eligibility to join this study. The inclusion criteria were: (1) age ≥ 5 years; (2) diagnosis of acute leukemia including acute myeloid leukemia, acute lymphocytic leukemia, and mixed phenotype acute leukemia; (3) patients attained complete remission (CR) and achieved full engraftment with 100% donor chimerism following allo-HSCT; (4) telomere testing was conducted on peripheral leukocytes of donors before granulocyte colony-stimulating factor (G-CSF) mobilization, and the results were obtained. Written informed consent was obtained from all included patients and their donors, and the study was conducted in compliance with the Declaration of Helsinki. Ethical approval was approved by the ethics review committee of the First Affiliated Hospital of Zhejiang University School of Medicine.
Interventions
OTHERNo intervention, observation study
No intervention, observation study
Sponsors
Zhejiang University
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
5 Years to 90 Years
Healthy volunteers
Yes
Inclusion criteria
* Age ≥ 5 years * First allo-HSCT from matched related, unrelated, or haploidentical donors * Achievement of complete remission after allo-HSCT * Donor blood sample collection before granulocyte colony-stimulating factor mobilization
Exclusion criteria
* Non-acute leukemia diagnoses, including acute myeloid leukemia, acute lymphocytic leukemia, and mixed phenotype acute leukemia * Failure to achieve engraftment with full donor chimerism after allo-HSCT * Inability to extract DNA for telomere length analysis.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Overall survival | From date of transplantuntil the date of death from any cause, assessed up to 60 months. | The duration from transplant until death resulted from any cause. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Relapse-free survival | From date of transplant until the date of relapse or death from any cause, assessed up to 60 months. | The time from transplant until death or relapse. |
| Cumulative incidence of relapse | From date of transplant until the date of relapse, assessed up to 60 months. | The time interval between the transplant and the occurrence of relapse. |
Countries
China
Contacts
Primary ContactHe Huang, PhD&MD
Outcome results
None listed